SR-2508

Complete pharmacological data from 71 patients treated on the phase I trial of SR 2508 were analyzed to see if the dose-limiting… Expand

Sixty-five patients were entered on the long schedule of the Phase I trial of SR-2508. The planned total doses ranged from 30 to… Expand

We have recently demonstrated that intracellular elevation of glutathione (GSH) by oxothiazolidine 4-carboxylate lessens SR-2508… Expand

Depletion of intracellular glutathione (GSH) can enhance misonidazole (MISO) radiosensitizing efficacy both in vivo and in vitro… Expand

From March 15, through August 31, 1983, 37 patients have been entered on the RTOG Phase I trial of SR-2508. The drug was given… Expand

We have used the RIF-1 tumor implanted intradermally in the lower dorsum of C3H mice to explore to what extent the… Expand

The lack of positive results from the clinical trials undertaken so far with misonidazole (MISO) are widely considered as… Expand

Abstract Using a combination of toxicological, pharmacological and radiosensitization experiments on cells in vitro and tumors in… Expand

Ten 2-nitroimidazole radiosensitizers of electron affinity equal to that of misonidazole, but differing in their octanol:water… Expand

The behavior of three 2-nitroimidazole drugs of similar electron affinity to misonidazole but with varying octanol: water… Expand